<ref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="B113"><label>113</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spyropoulos</surname><given-names>AC</given-names></name><name><surname>Goldin</surname><given-names>M</given-names></name><name><surname>Giannis</surname><given-names>D</given-names></name><name><surname>Diab</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Khanijo</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial</article-title>. <source>JAMA Intern Med</source>. (<year>2021</year>) <volume>181</volume>:<page-range>1612&#8211;20</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jamainternmed.2021.6203</pub-id>, PMID: <?supplied-pmid 34617959?><pub-id pub-id-type="pmid">34617959</pub-id>
</mixed-citation></ref>